Pradhan R, Lu S, Yin H Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. BMJ. 2022; 379

Rogliani P, Matera MG, Calzetta L Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respir Med. 2019; 154:86-92

Chronic obstructive pulmonary disease: potential new treatments

02 February 2023
Volume 28 · Issue 2

Drugs known for their favourable cardiovascular effects may also benefit the respiratory system. There has been interest in exploring whether such treatments could therefore provide relief for the estimated 1.2 million people living across the UK with chronic obstructive pulmonary disease (COPD)—a disabling lung condition.

Pradhan et al (2022) examined whether the use of the receptor agonist glucagon-like peptide 1 (GLP-1), dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 (SGLT-2) inhibitors, separately, are associated with a lower risk of COPD exacerbations among a patient cohort with COPD and type 2 diabetes.

The researchers assessed factors such as whether each drug was linked with, for example, a decreased risk of developing a moderate exacerbation (the researchers defined this as a co-prescription of an oral corticosteroid and an antibiotic, along with an outpatient diagnosis of acute COPD exacerbation that same day). The results showed that when compared with sulfonylureas, GLP-1 receptor agonists were found to be associated with a 30% reduced risk of a severe exacerbation (3.5 v 5.0 events per 100 person years) and moderate exacerbation. DPP-4 inhibitors were also observed to be associated with a modestly decreased incidence of severe exacerbation (4.6 v 5.1 events per 100 person years) and moderate exacerbation. The team also observed that SGLT-2 inhibitors were associated with a 38% lower risk of severe exacerbation (2.4 v 3.9 events per 100 person years), but these were not seen to have any effect on the risk of developing moderate exacerbation.

Register now to continue reading

Thank you for visiting Community Nursing and reading some of our peer-reviewed resources for district and community nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • New content and clinical newsletter updates each month